This article is mentioned in:

Introduction

Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer-associated death among females worldwide. There were an estimated 1.7 million cases of breast cancer and 521,900 deaths in 2012, accounting for ~25% of all cancer diagnoses and 15% of all cancer-associated deaths in women (1). Breast cancer is a highly heterogeneous disease that is classified into five different molecular subtypes based on the presence or absence of estrogen receptors (ERs), progesterone receptors (PRs) and human epidermal growth factor receptor 2 (HER2/neu) (2). Among the five subtypes, the most commonly observed subtypes in clinical practice are Luminal A, Luminal B, HER2+ and triple-negative breast cancer (TNBC). Luminal A is associated with ER and PR expression, and represents 50–60% of all breast cancer cases, luminal B is ER+, PR+/− and HER2+/−, and represents 10–20% of all breast cancer cases, and HER2+ is characterized by HER2/neu upregulation and represents ~20% of all breast cancer cases. TNBC is negative for ER, PR and Her2/neu, and constitutes ~20% of all breast cancer cases (3,4). As the five subtypes exhibit distinct gene expression profiles, mutational spectrum and copy number variations, each subtype has unique histological characteristics, biological and clinical behaviors, and prognostic features (3). Metastasis is responsible for 90% of all cancer-associated deaths and is the primary clinical challenge of treating solid tumors (5). Therefore, investigating the mechanisms underlying metastasis is important for improving breast cancer therapy and prognosis.

Stanniocalcin-1 (STC1) is a 56-kDa disulfide-bound glycoprotein hormone that was first identified in bony fish and is involved in plasma calcium and phosphate homeostasis (6). Human STC1 was identified as a differentially expressed mRNA associated with cellular immortalization, a key feature of the cancer cell phenotype (7). The human STC1 gene maps to chromosome 8p21-p11.2, which shares 73% homology with the fish Stc gene and encodes a 247-amino acid protein. STC1 exists as a homodimer, and through the presence of a signal peptide, it is secreted into the extracellular matrix in an autocrine or paracrine manner (7–10). Mammalian STC1 is expressed in various tissues, including the endocrine glands and hormone-responsive organs (11). Among all tissues, the ovaries contain the highest STC1 expression levels, with elevated expression observed during pregnancy and lactation (11). STC1 has been implicated in multiple physiological and pathophysiological processes, including, but not limited to, pregnancy, angiogenesis, organogenesis, cell proliferation, apoptosis, suppression of oxidative stress, retinal degeneration, cerebral ischemia and inflammation (10,12–14). In addition, accumulating evidence has suggested that the aberrant expression of STC1 serves a role in various types of cancer. STC1 triggers tumor angiogenesis by upregulating the expression of vascular endothelial growth factor in gastric cancer cells (15). Abnormal STC1 expression is also typically associated with tumorigenesis and poor clinical outcomes in ovarian, colorectal and lung cancer (16–18). Therefore, STC1 confers a malignant phenotype to various types of cancer. However, the clinical significance of STC1 expression in breast cancer has not been well established. At present, studies have primarily focused on the association between STC1 and breast cancer invasion and metastasis (19–22). However, other studies have suggested that STC1 is involved in tumor growth and chemotherapy resistance in breast cancer (20,22,23). Emerging evidence has shown that STC1 is a novel biomarker that may be useful for predicting the recurrence and prognosis of breast cancer (19,21,22,24–27). However, whereas some studies have demonstrated an oncogenic role for STC1 in breast cancer (20,22,26,28), other studies have reported contradictory results (27,29,30). Accordingly, it is necessary to elucidate the roles of STC1 in breast cancer.

STC2 is a paralog of STC1 that was identified by searching expressed sequence tag databases for sequences related to STC1 (31–33). The human Stc2 gene localizes to chromosome 5q33 or 5q35 (34,35), which encodes a protein containing 302 amino acids and shares 34% identity with both STC1 and eel STC (12). Similar to STC1, human STC2 is abundantly expressed in tissues, including the kidney, heart, pancreas and spleen (31–33). STC2 was first associated with breast cancer in a study designed to identify estrogen-regulated genes in breast cancer cell lines (36). Previous studies suggested that STC2 expression is inducible by estrogen and repressed by anti-estrogens (36,37). In addition, STC2 was demonstrated to be induced by retinoic acid and progesterone in a number of breast cancer cell lines. In addition, STC2 acts in a paracrine or autocrine manner in hormone receptor-negative cell lines (36,38). Iwao et al (39) first reported the clinical significance of STC2 expression in breast cancer. A total of 21 genes with prognostic value in breast cancer were identified, and low expression of these genes, including STC2, was associated with a poor prognosis (39). Yamamura et al (40) demonstrated that high STC2 expression was significantly associated with a favorable prognosis in patients with ER− and PR+ breast cancer. Results of a tissue microarray screen showed that STC2 expression was associated with longer disease-free survival times (41). In 2008, Raulic et al (38) showed that constitutive STC2 expression impaired cell growth, viability and migration, suggesting that STC2 inhibits cell proliferation and motility. In a recent study, Coulson-Gilmer et al (42) reported that STC2 expression was associated with favorable outcomes in male breast cancer, where it served as an independent prognostic factor for disease-free survival. However, the mechanisms underlying the favorable clinical outcomes associated with STC2 remain unknown. Several studies have indicated the involvement of STC2 in the pregnancy-associated plasma protein-A (PAPP-A)-insulin like growth factor (IGF)-binding protein 4-IGF axis, as STC2 was demonstrated to potently inhibit PAPP-A activity by forming a covalent complex with PAPP-A (43–47). Additional studies are required to confirm these findings. Taken together, the aforementioned studies suggest that STC2 expression is associated with a more differentiated phenotype and improved prognosis in patients with breast cancer.

The aim of the present review is to elucidate the role of STC1 in breast cancer and the potential underlying mechanisms.

STC1 is implicated in TNBC invasion and metastasis

TNBC is a highly aggressive disease that is often associated with a poor prognosis and is more frequently diagnosed in younger women (<50 years old) (48–52). Given the lack of specific therapeutic targets, TNBC is insensitive to anti-hormonal and HER2-targeted therapies. At present, chemotherapy remains the primary treatment option for patients with TNBC (53). Although patients with TNBC are sensitive to chemotherapy, they often experience aggressive biological and clinical characteristics associated with an advanced histological grade, including rapid proliferation, shorter time to recurrence and higher risk of distant recurrence (51). Therefore, a number of studies have attempted to discover promising therapeutic targets for treating TNBC.

Recent studies have suggested that STC1 serves an oncogenic role in TNBC and is associated with invasion and metastasis. Murai et al (20) demonstrated that STC1 overexpression enhanced cell invasion in the human TNBC MDA-MB-231 cell line in vitro and promoted the pulmonary metastasis of the cells in vivo. Consistent with these findings, another study showed that STC1-knockdown reduced cell invasiveness and metastasis in murine and MDA-MB-231 cell lines (22). Furthermore, similar outcomes were observed in two other studies conducted by Han et al (19) and Jeon et al (21), in which elevated levels of STC1 were found to significantly increase the invasiveness and metastasis of TNBC cells.

The detailed mechanism by which STC1 stimulates TNBC cell invasion and metastasis remains to be fully elucidated. However, certain studies have shed light on this issue. Huang et al (54) showed that macrophage-capping protein, a metastasis-associated gene, inhibited the activity of arginine methyltransferase 5, a metastasis-suppressing gene that binds to the same region (−451 to −75 bp) in the STC1 promoter, which in turn promoted STC1 transcription and enhanced breast cancer metastasis. Another study reported contradictory results, suggesting that STC1 expression was upregulated via the phosphoinositide 3-kinase/protein kinase B (PI-3k/Akt) or nuclear factor-κB (NF-κB)-dependent signaling pathway in TNBC cells. Furthermore, the results indicated crosstalk between the Akt and NF-κB signaling pathways in the regulation of STC1 expression, as active Akt overexpression increased the phosphorylation levels of NF-κB (21). Taken together, the results demonstrated that STC1 promotes the metastasis of TNBC cells by upregulating STC1 expression via the PI-3K/Akt/NF-κB-dependent signaling pathways (21). Han et al (19) demonstrated that high STC1 expression levels significantly increased the invasiveness of TNBC cells and that the process was mediated by phosphorylation of JNK/c-Jun, which in turn upregulated the expression of MMP-9.

Based on the pooled data, a schematic model of STC1 promoting the invasion and metastasis of TNBC can be hypothesized. First, STC1 expression levels are elevated via the PI-3K/Akt/NF-κB signaling pathways. In turn, elevated STC1 levels promote MMP-9 transcriptional activity by activating the JNK/c-Jun signaling pathway and triggering the invasion and metastasis of TNBC cells (Fig. 1). Therefore, STC1 may be a promising therapeutic target for the treatment of TNBC.

Figure 1. STC1 expression and cell invasion. STC1 expression is increased via a PI-3K/Akt/NF-κB-dependent signaling pathway. STC-1 protein is subsequently secreted into the extracellular matrix in an autocrine/paracrine manner. Secreted STC1 binds to its receptors on the surface of the cell membrane to form a complex which initiates the JNK/c-Jun signaling pathway. Activated c-Jun dimerizes with the Fos family of proteins to form AP-1, which activates MMP-9 transcriptional activity. Finally, increased MMP-9 expression results in increased cell invasion of triple-negative breast cancer cells as a result of extracellular matrix degradation. STC1, stanniocalcin-1; PI-3K, phosphoinositide 3-kinase; Akt, protein kinase B; NF-κB, nuclear factor-κB.

STC1 expression as a prognostic factor in breast cancer

Several prognostic markers for breast cancer are used in contemporary clinical practice, including carcinoembryonic antigen, ER, PR and HER2 (55,56). However, these individual markers cannot be reliably used to predict prognosis due to lack of specificity or sensitivity to breast cancer. Recently, multiple studies have indicated that the protein and mRNA expression levels of STC1 in tumors may be used as a valuable prognostic marker of breast cancer. McCudden et al (24) suggested that patients with breast cancer with strong positive staining for STC1 and its receptor had an increased incidence of lymph node involvement and ductal carcinoma in situ status. Similarly, Wascher et al (26) reported that STC1 mRNA levels in the bone marrow and blood of patients with breast cancer were significantly associated with the primary tumor size, number of positive lymph nodes and overall American Joint Committee on Cancer stage (57). In addition, the study highlighted the potential use of STC1 as a highly sensitive potential molecular marker for occult breast cancer cells in the bone marrow and blood of patients with breast cancer (26). STC1 may be used to identify subclinical metastatic breast cancer disease before it becomes clinically and radiographically visible (26). A retrospective study of 1,457 clinical samples found a significant association between high STC1 expression and a poor clinical outcome (22). However, Zandberga et al (25) showed that there was no significant association between STC1 levels and relapse-free survival (RFS), overall survival (OS) or distant metastasis-free survival (DMFS) when all patients with breast cancer were analyzed together without considering the intrinsic molecular subtypes separately. Breast cancer is a highly heterogeneous disease, and different breast cancer subtypes have different prognoses. Furthermore, some studies have indicated the potential predictive value of STC1 in different subtypes of breast cancer (Table I).

Table I. STC1 expression and the prognosis of BC subtypes.

Table I.

STC1 expression and the prognosis of BC subtypes.

Author, year	Country	Breast cancer subtype	Outcome	Expression level of STC1 in BC	Predictive value of STC1 expression in BC	(Refs.)
McCudden et al 2004	Canada	All subtypes	Tumor size, blood and lymphatic invasion	High	Poor prognosis	(24)
Wascher et al 2003	America	All subtypes	Tumor size, number of positive lymph nodes, T stagea, M stagea, N stagea, overall AJCC stagea	NA	Poor prognosis	(26)
Chang et al 2015	Australia	All subtypes	Tumor growth, metastasis	High	Poor prognosis	(22)
Zandberga et al 2017	Latvia	Basal	RFS, OS, DMFS	NA	Poor prognosis	(25)
		Luminal A	RFS, OS, DMFS	NA	NC
		Luminal B	RFS, OS, DMFS	NA	Poor prognosis
		HER2+	RFS, OS, DMFS	NA	NC
Han et al 2016	Korea	TNBC	RFS, OS	High	Poor prognosis	(19)
	Korea	Non-TNBC	RFS, OS	High	NC
Jeon et al 2016	Korea	TNBC	RFS, OS	High	Poor prognosis	(21)
		Luminal	RFS, OS	Low	NC
		HER2+	RFS, OS	Low	NC
Welcsh et al 2002	America	All subtypes	Level of BRCA1 and STC1 expression	Low	Good prognosis	(30)
Joensuu et al 2008	Finland	Hormone receptor-positive	Recurrence, metastasis	High	Good prognosis	(29)
Brantley et al 2018	America	ER+/TAM+	Recurrence	Higher	Good prognosis	(27)
		ER−/TAM−	Recurrence	Lower	Good prognosis

a Amin MB, Edge S, Greene F, et al: AJCC Cancer Staging Manua[M]. 8th ed. New York: Springer, 2017. STC1, stanniocalcin-1; BC, breast cancer; TNBC, triple-negative breast cancer; DMFS, distant metastasis-free survival; NC, no correlation; NA, not available, TAM⁻, tamoxifen-untreated; TAM⁺, tamoxifen-treated; ER⁺, estrogen receptor-positive; HER2⁺, human epidermal growth factor receptor 2; OS, overall survival; RFS, relapse-free survival.

STC1 expression as a prognostic factor in TNBC

Multiple studies have shown that STC1 expression is upregulated in TNBC compared with that in other breast cancer subtypes and that it is associated with poor survival in patients with TNBC (19,21,25). Zandberga et al (25) performed independent analysis of the intrinsic molecular subtypes and reported that upregulated expression of STC1 was significantly associated with shorter OS and RFS times in patients with the basal-type breast cancer (defined as ER−/HER2−), but not with the luminal A and HER2+ subtypes. In the luminal B subtype, high STC1 expression was associated with a shorter DMFS time, but not with RFS and OS times. Furthermore, the association between high STC1 expression and shorter OS and RFS times was more evident when a subgroup of tumor protein p53 (TP53)-mutated basal-type breast cancer cases was analyzed. Taken together, the aforementioned findings suggested that in basal-type breast cancer, patients with upregulated expression of STC1 had a poor prognosis, and that patients with TP53 mutations in addition to high STC1 expression had a considerably less favorable prognosis (25). Han et al (19) and Jeon et al (21) showed that STC1 expression levels were significantly higher in TNBC cells than in non-TNBC cells. Patients of TNBC with high STC1 levels had shorter RFS and OS times. The conclusion of the two studies was that elevated STC1 expression was associated with a poor prognosis in patients with TNBC (19,21).

Therefore, based on the results of the aforementioned studies, STC1 expression appears to be significantly higher in TNBC cells compared with that in non-TNBC cells. Furthermore, elevated STC1 expression is associated with a poor prognosis in patients with TNBC and promotes the invasiveness and metastasis of TNBC cells.

STC1 expression as a prognostic factor in hormone receptor-positive breast cancer

STC1 expression was found to be correlated with ER status, and STC1 receptors and ER are typically co-expressed in breast cancer (24). Furthermore, STC1 was expressed in only a subset of ER+ breast cancer, which is a marker for favorable prognosis in breast cancer (12,24,37). Bouras et al (37) reported that expression levels of STC1 and STC2 were more clinically useful than ER status. Furthermore, the tumor suppressor genes BRCA1 DNA repair-associated (BRCA1) and P53 were reported to induce STC1 expression (30). STC1 was found to be expressed in normal breast ductal epithelium, and loss of BRCA1 and STC1 expression was correlated in breast cancer (30). The two genes, BRCA1 and TP53, which are both tumor-suppressor genes and their proteins in cancer are usually associated with favorable prognosis (58–60).

In a study consisting of 72 primary breast cancer tissues and the corresponding metastatic tissues, STC1 expression levels were significantly higher in the metastases 5 and 10 years after surgery compared with those in the primary tumors with early metastases (29). Elevated STC1 expression contributed to tumor dormancy and was indicative of a risk for late recurrence (29). Similarly, another large study followed 3,634 Danish patients with breast cancer, including 1,826 ER+ tamoxifen-treated (TAM+) patients and 1,808 ER− tamoxifen-untreated patients (TAM−) who survived for at least 1 year without recurrence (27). The results showed that STC1 expression was higher, on average, among ER+/TAM+ patients compared with that among ER−/TAM− patients. In addition, the study found an association between STC1 expression and recurrence in the primary tumors of women who experienced recurrence 6–10 years following primary diagnosis, but not in the tumors of women who experienced earlier recurrence (27). However, another study showed that there was no association between STC1 expression levels and the survival of patients with luminal-type breast cancer (21). In general, it was suggested that high STC1 levels are associated with a favorable prognosis in hormone receptor-positive breast cancer based on the pooled studies.

Association between STC1 expression and prognosis of HER2+ breast cancer

There are only two studies that have demonstrated the correlation between STC1 expression and the prognosis of HER2+ breast cancer. The conclusions of the two studies were consistent with each other and suggested that there was no correlation between STC1 expression and the prognosis of patients with HER2+ breast cancer (21,24,25). Considering the small number of studies on the HER2+ subtype, further studies are required to validate these findings.

Effect of STC1 expression on the proliferation of breast cancer cells

Certain studies have reported that STC1 alters cell proliferation. However, the effect of STC1 expression on cell proliferation was found to vary among different types of cancer. STC1 was demonstrated to inhibit the proliferation of cervical cancer cells (61), but promoted tumor proliferation and cell colony formation in ovarian cancer. The potential mechanism underlying this observation may involve increasing the activity of cell cycle-regulated proteins and anti-apoptotic proteins, as well as inhibiting the activity of caspase-3/caspase-9 (17). Similarly, the conclusions of studies reporting the effects of STC1 on breast cancer proliferation were inconsistent. Welcsh et al (30), and Daniel and Lange (62) reported that STC1 contributes to breast cancer cell proliferation. Interestingly, in an independent experiment, it was observed that downregulation of STC1 expression slowed the rate of tumor growth in both murine and human breast cancer cells in vivo, but had no effects on proliferation in both models in vitro (22). Therefore, additional studies are required to further verify the effects of STC1 on breast cancer cell proliferation based on the intrinsic molecular subtype.

Correlation between STC1 expression and breast cancer chemotherapy resistance

Previous studies have shown that the aberrant expression of STC1 is involved in the chemotherapy resistance of various tumors. Liu et al (63) focused on investigating the microenvironment of lung cancer cells and identified a correlation between STC1 expression and chemotherapy resistance in lung cancer cells. Shirakawa et al (64) reported a similar conclusion in esophageal squamous cell carcinoma. Only one retrospective study from China indicated that STC1 expression in breast cancer tissue was associated with chemotherapy resistance in patients with breast cancer (23). Furthermore, the molecular mechanism mediating chemotherapy resistance remains unknown. Multiple studies have reported that STC1 expression is induced by hypoxia (16,65–69). Hypoxia-inducible factor-1α, which is involved in the chemotherapy resistance of tumor cells (70–72), can bind to the STC1 promoter and regulate its transcription (16,65–69). Based on these studies, we hypothesize that this is the mechanism underlying STC1-mediated chemotherapy resistance. However, further studies are required to examine and confirm the exact molecular mechanism underlying tumor chemotherapy resistance.

Conclusions

The roles of STC1 are complicated and varied in breast cancer. Furthermore, STC1 exhibits varying functions and prognostic value dependent on the breast cancer subtype. In TNBC, STC1 serves an oncogenic role and promotes invasiveness and metastasis. Furthermore, patients with TNBC with elevated levels of STC1 expression had poor prognosis. Accordingly, STC1 may serve as a promising therapeutic target for the treatment of TNBC. However, in hormone receptor-positive breast cancer, high STC1 expression levels were correlated with a favorable prognosis, but in HER2+ breast cancer, there was no correlation between STC1 expression and the prognosis. Similarly, the effects of STC1 expression on breast cancer cell proliferation are controversial. In this regard, tumor source, distinct gene expression and variability are likely to be at least partially responsible for the contrasting results. In addition, a few studies have suggested that STC1 expression is correlated with the chemotherapy resistance of breast cancer; however, the exact mechanism remains unknown. Some studies have also reported that STC1 may be used to identify subclinical metastatic breast cancer disease before it is clinically and radiographically visible. Therefore, STC1 may be a promising novel molecular marker and therapeutic target for the clinical diagnosis, treatment and prognosis evaluation of patients with breast cancer.

The present review contributes to the understanding of the role of STC1 in breast cancer and hypothesizes a mechanism by which STC1 may contribute to resistance to chemotherapy. The different roles of STC1 in the development of breast cancer were classified and discussed. The prognostic value of STC1 in breast cancer based on subtype was highlighted and is summarized in Table I. A conclusion was drawn based on combined results of the studies referenced, suggesting a potential schematic model by which STC1 promotes the invasion and metastasis of TNBC.

However, there are certain limitations in the present review. Only a limited number of studies have investigated the role of STC1 in breast cancer, therefore, the conclusions drawn in the present review are based on a small number of studies. Additionally, some of the studies referenced did not analyze the role of STC1 based on breast cancer subtype, which may have masked the role of STC1 in these studies as it seems to display opposing effects based on the subtype. Some of the clinical studies reference retrospective studies with small sample size, thus extrapolation of the results from these studies to the wider population should be performed with caution. Finally, the mechanism by which STC1 participates in various pathophysiological processes in breast cancer remains to be fully elucidated. Therefore, larger clinical and experimental studies are required to verify the role of STC1 in breast cancer, as well as the potential mechanisms underlying its effects.

Acknowledgements

Not applicable.

Funding

The present review was supported by Scientific Research Program of Wuhan Health and Family Planning (grant nos. WX17Q38 and WZ18Q05) and The Research Program of Wuhan No. 1 Hospital, Wuhan Integrated TCM & Western Medicine Hospital (grant no. 2017Y01).

Availability of data and materials

Data sharing is not applicable to this article, as no datasets were generated or analyzed during the current study.

Authors' contributions

FC, ZZ and FP contributed to data analysis and writing of the manuscript. ZZ was involved in the conception of the study. FC and FP were involved in the literature search for this systematic review. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References